TITLE

MERZ + CO./FOREST LABS SIGN PACT FOR MEMANTINE DEVELOPMENT

PUB. DATE
August 2000
SOURCE
Worldwide Biotech;Aug2000, Vol. 12 Issue 8, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Announces that Merz + Co. has entered into an agreement with Forest Laboratories Inc. for the development and marketing of Memantine drugs in the United States.
ACCESSION #
3449622

 

Related Articles

  • Pfizer Inc's (New York) dementia drug Aricept, already commonly used to treat mild to moderate Alzheimer's disease, can also help patients with severe disease and should be used more widely and for longer, according to research published last week.  // MondayMorning;3/12/2012, Vol. 20 Issue 11, p1 

    The article discusses the benefits of continued treatment with the drug, Aricept which helps in treating patients with moderate to severe Alzheimer. It informs that the first trial to check the effect of extended drug treatment was conducted by professor Robert Howard. It informs that the drug...

  • Drugmaker Forest branches out. Benson, Barbara // Crain's New York Business;10/16/95, Vol. 11 Issue 42, p31 

    Profiles drug marketing company Forest Laboratories Inc. Reputation as a small niche firm; Marketing strategy placing Forest in direct competition with major pharmaceutical companies; Acquisition of products such as Climara and Tiazac.

  • Local drug company swallows bitter pill: First year of losses. Temes, Judy // Crain's New York Business;05/26/97, Vol. 13 Issue 21, p3 

    Reports that Forest Laboratories Incorporated recorded a $25 million loss in its fiscal year which ended March 31, 1997. Decrease in the revenue of the company; Information on the company's plans for growth; Reason for the Forest Laboratories' losses.

  • Forest Laboratories: Beyond the trees. Reingold, Jennifer // FW; 

    Presents a financial profile of Forest Laboratories. Appraisal and forecasting of stock price; Appraisal of consumer demand for the firm's drugs; Drugs currently being developed; Potential for further profits.

  • Forest growing at 155 Commerce. Anastasi, Nick // Long Island Business News (7/1993 to 5/2009);03/24/2000, Vol. 47 Issue 12, p5A 

    Reports on drug developer Forest Laboratories' lease of a site in Long Island, New York. Reason for leasing the site; Renovation of the site; Net sales of the firm for fiscal year ending December 31, 1999.

  • TEFLARO.  // MPR - Residents' Edition;Spring/Summer2011, Vol. 20 Issue 1, pA.7 

    The article offers brief information on the antibiotic drug Teflaro from Forest Laboratories Inc.

  • Antidepressant Sales Could Reach $600 Million.  // Drug Store News;10/19/98, Vol. 20 Issue 17, pCP20 

    Forecasts the sales of Forest Laboratories' antidepressant Celexa by year 2002. Company's plans to increase its sales.

  • Banking on sales. Horton, Kathleen // Pharmaceutical Executive;Aug97, Vol. 17 Issue 8, p96 

    Announces Forest Laboratories Inc.'s completion of its financial plans for the clinical development, launching and marketing of its depression treatment medicine Citalopram.

  • Forest to bid.  // Crain's New York Business;9/18/95, Vol. 11 Issue 38, p50 

    Reports on Forest Laboratories Inc.'s plan to announce a tender offer of 22% of Biovail Corp. International as part of a licensing agreement for Biovail's approved heart drug.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics